Daily Use of Sildenafil Improves Endothelial Function in Men With Type 2 Diabetes

Abstract

Diminished vascular endothelial function results in decreased vasodilator capacity and is associated with erectile dysfunction (ED) in patients afflicted with type 2 diabetes. The current study was designed to evaluate whether daily use of sildenafil could alter endothelial function and improve penile rigidity in a group of patients with diabetic ED. A double-blind, placebo-controlled, prospective trial was conducted with 24 men with type 2 diabetes who were randomized into 2 groups: one receiving daily sildenafil (50 mg, n 5 12) and the other placebo (n 5 12) for 10 weeks. Erectile function was captured subjectively using the International Index of Erectile Function (IIEF-5), and endothelial function was objectively monitored via brachial artery flow-mediated dilation. Among the placebo and sildenafil groups, there were no significant differences in average patient age, time from type 2 diabetes diagnosis, duration of ED, or baseline IIEF-5 scores. Past medical histories, including smoking, alcohol consumption, hypertension, and hyperlipidemia, were also similar. At the conclusion of the 10-week trial, patients who received daily sildenafil had significantly improved erectile rigidity as captured by IIEF-5 (P , .001) and increased endothelial function via brachial artery flow-mediated dilation (P , .01). Endothelial function in men with type 2 diabetes was enhanced with daily sildenafil. Improved erectile rigidity and enhanced vascular circulation was noted after 10 weeks of daily sildenafil use.

Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial

“…Data from the literature demonstrate an FMD improvement after chronic (13,24,25,26,27) and acute sildenafil administration in diabetic men (28). By using vardenafil, here, we demonstrate that FMD improves during treatment.…”

THERAPY OF ENDOCRINE DISEASE: Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis

“…All trials were thoroughly appraised for their eligibility in the metaanalysis and their methodological quality. Six studies met the inclusion criteria (29,30,35,36,37,38) (Table 1). Ten studies were excluded from the final analysis as they did not fulfill inclusion criteria.…”

“…All trials included in the meta-analysis (29,30,35,36,37,38) enrolled men with T2DM based on the definition of WHO (49). T2DM was defined in the same way in the six included studies, but a different duration of the disease was reported in the inclusion criteria of each RCT ( Table 1).…”

“…All trials included in the meta-analysis (29,30,35,36,37,38) considered the chronic administration of PDE5i. In particular, all studies provided the use of the same PDE5i: Sildenafil citrate.…”

Evaluating of the phosphodiesterase inhibitor type 5 effectiveness in treatment of neurogenic erectile dysfunction in patients with DM type 1

“…В пользу применения ингибиторов ФДЭ-5 (иФДЭ-5) при СД говорят также, результаты двой-ного слепого плацебо-контролируемого исследова-ния [12], в котором была показана высокая эффек-тивность курсового применения силденафила для улучшения эректильной функции пациентов. Уста-новлено также улучшение NO-синтетической ак-тивности эндотелиоцитов в условиях инсулиноре-зистентности у больных с СД [13].…”